文献速递心力衰竭与心肌病

长寿基因、心脏衰老与心肌病发病机制:对当前及未来心衰治疗意义的解读

Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.
PubMed 文献 · Eur Heart J · 2020-01-01

本文综述了SIRT1/PGC-1α/AMPK通路激活与Akt/mTORC1通路抑制通过增强自噬来延缓心脏衰老、减轻心肌病的作用机制。实验表明,这些通路的失衡是心肌病的特征,而逆转这些异常可减轻心衰发展;多数临床有效的慢性射血分数降低心衰治疗药物在实验中可促进自噬流。

要点

  • SIRT1/PGC-1α/AMPK激活与mTORC1抑制通过增强自噬发挥心脏保护作用。
  • 自噬基因沉默可消除上述通路激活带来的延寿和减轻心肌病益处。
  • 多数临床有效的心衰药物在实验中可激活SIRT1通路和/或抑制mTORC1。

核心结论

  • 长寿基因信号通路紊乱导致的自噬受损可能是心肌病发生和进展的关键事件。

研究设计与样本

  • 本文为综述,围绕SIRT1和mTORC1两条通路及其对心脏衰老和心肌病的作用进行机制性总结。

主要发现

  • 激活SIRT1/PGC-1α/AMPK和抑制Akt/mTORC1可延长寿命、延缓心脏衰老,并在实验模型中产生心脏保护效应。
  • 这些保护作用与调节氧化应激、细胞器功能、促炎通路和不良性肥厚有关,且共同受益于增强自噬。
  • 自噬基因沉默可消除SIRT1/PGC-1α/AMPK激活和Akt/mTORC1抑制带来的延寿、减轻心脏衰老和缓解心肌病等益处。
  • SIRT1/PGC-1α/AMPK功能丧失或Akt/mTORC1过度激活是实验性心肌病的持续特征,逆转这些异常可减轻心衰发展。
  • 多数临床有效的慢性射血分数降低心衰治疗药物在实验中可激活SIRT1/PGC-1α/AMPK和/或抑制Akt/mTORC1,从而促进自噬流。

临床怎么用

  • 理解现有心衰治疗药物可能通过调节长寿基因信号和增强自噬发挥作用,为机制性用药提供思路。
  • 未来治疗策略可考虑靶向SIRT1/PGC-1α/AMPK激活或Akt/mTORC1抑制以促进自噬。

局限性

  • 本文为综述,主要基于实验模型证据,临床转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The two primary molecular regulators of lifespan are sirtuin-1 (SIRT1) and mammalian target of rapamycin complex 1 (mTORC1). Each plays a central role in two highly interconnected pathways that modulate the balance between cellular growth and survival. The activation of SIRT1 [along with peroxisome proliferator-activated receptor-gamma coactivator (PGC-1α) and adenosine monophosphate-activated protein kinase (AMPK)] and the suppression of mTORC1 (along with its upstream regulator, Akt) act to prolong organismal longevity and retard cardiac ageing. Both activation of SIRT1/PGC-1α and inhibition of mTORC1 shifts the balance of cellular priorities so as to promote cardiomyocyte survival over growth, leading to cardioprotective effects in experimental models. These benefits may be related to direct actions to modulate oxidative stress, organellar function, proinflammatory pathways, and maladaptive hypertrophy. In addition, a primary shared benefit of both SIRT1/PGC-1α/AMPK activation and Akt/mTORC1 inhibition is the enhancement of autophagy, a lysosome-dependent degradative pathway, which clears the cytosol of dysfunctional organelles and misfolded proteins that drive the ageing process by increasing oxidative and endoplasmic reticulum stress. Autophagy underlies the ability of SIRT1/PGC-1α/AMPK activation and Akt/mTORC1 suppression to extend lifespan, mitigate cardiac ageing, alleviate cellular stress, and ameliorate the development and progression of cardiomyopathy; silencing of autophagy genes abolishes these benefits. Loss of SIRT1/PGC-1α/AMPK function or hyperactivation of Akt/mTORC1 is a consistent feature of experimental cardiomyopathy, and reversal of these abnormalities mitigates the development of heart failure. Interestingly, most treatments that have been shown to be clinically effective in the treatment of chronic heart failure with a reduced ejection fraction have been reported experimentally to exert favourable effects to activate SIRT1/PGC-1α/AMPK and/or suppress Akt/mTORC1, and thereby, to promote autophagic flux. Therefore, the impairment of autophagy resulting from derangements in longevity gene signalling is likely to represent a seminal event in the evolution and progression of cardiomyopathy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Packer M. Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure. Eur Heart J. 2020. PMID: 32460327. doi:10.1093/eurheartj/ehaa360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。